Pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration in normal women and men

Neuropsychopharmacology

Volumn 20, Issue 5, 1999, Pages 434-446

  Rubin, Robert T ^a   Sekula, L Kathleen ^a   O'Toole, Susan ^a   C S , ^a   M S N , ^a   Rhodes, Michael E ^a   Czambel, R Kenneth ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

ACTH; AVP; Cholinergic; Cortisol; Physostigmine; Sex differences

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; GLYCOPYRRONIUM BROMIDE; HYDROCORTISONE; PHYSOSTIGMINE;

ADULT; ARTICLE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEADACHE; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADRENAL SYSTEM; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE CRAMP; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE;

ADRENOCORTICOTROPIC HORMONE; ADULT; AREA UNDER CURVE; ARGININE VASOPRESSIN; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROCORTISONE; MALE; PARASYMPATHOMIMETICS; PHYSOSTIGMINE; PITUITARY-ADRENAL SYSTEM; PSYCHIATRIC STATUS RATING SCALES;

EID: 0033136909     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00077-3     Document Type: Article

References (61)

1. Aedo A.R., Landgren B.M., Diczfalusy E. Studies on ovarian and adrenal studies at different phases of the menstrual cycle IV. The effect of dexamethasone suppression and subsequent ACTH stimulation at different phases of the menstrual cycle and following the administration of 150 mg of depot-medroxy-progrsterone acetate (DMPA). Contraception. 24:1981;543-558.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (Third Edition-Revised). 1987;American Psychiatric Press, Washington DC.
3. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol. 14:1993;76-122.
4. Asplund R., Åberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Int Med. 229:1991;131-134.
5. Assenmacher I., Szafarcyzk A., Alonso G., Ixart G., Barbanel G. Physiology of neural pathways affecting CRH secretion. Ann NY Acad Sci. 512:1987;149-161.
6. Baldino F. Jr., O'Kane T.M., Fitzpatrick-McElligott S. Coordinate hormonal and synaptic regulation of vasopressin messenger RNA. Science. 241:1988;978-981.
7. Born J., Ditschuneit I., Schreiber M., Dodt C., Fehm H.L. Effects of age and gender on pituitary-adrenocortical responsiveness in humans. Eur J Endocrinol. 132:1995;705-711.
8. Calogero A.E. Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron. Ann NY Acad Sci. 771:1995;31-40.
9. Carroll B.J., Greden J.F., Haskett R., Feinberg M., Albala A.A., Martin F.I., Rubin R.T., Heath B., Sharp P.T., McLeod W.L., McLeod M.F. Neurotransmitter studies of neuroendocrine pathology in depression. Acta Psychiatr Scand Suppl. 280:1980;183-199.
10. Carroll B.T., Meller W.H., Kathol R.G., Gehris T.L., Carter J.L., Samuelsen S.D., Pitts A.F. Pituitary-adrenal axis response to arginine vasopressin in patients with major depression. Psychiatry Res. 46:1993;119-126.
11. Cirino M., Renaud L.P. Influence of lateral septum and amygdala stimulation on the excitability of hypothalamic supraoptic neurons. An electrophysiological study in the rat Brain Res. 326:1985;357-361.
12. Coiro V., Volpi R., Capretti L., Colla R., Caffarri G., Vescovi P.P., Chiodera P. Dopaminergic and cholinergic control of arginine-vasopressin secretion in type I diabetic men. Eur J Clin Invest. 25:1995;412-417.
13. Davis B.M., Brown G.M., Miller M., Friesen H.G., Kastin A.J., Davis K.L. Effects of cholinergic stimulus on pituitary hormone release. Psychoneuroendocrinology. 7:1982;347-354.
14. De Vries G.J., Wang Z., Bullock N.A., Numan S. Sex differences in the effects of testosterone and its metabolites on vasopressin messenger RNA levels in the bed nucleus of the stria terminalis of rats. J Neurosci. 14:1994;1789-1794. a.
15. De Vries G.J., Al-Shamma H.A., Zhou L. The sexually dimorphic vasopressin innervation of the brain as a model for steroid modulation of neuropeptide transmission. Ann NY Acad Sci. 743:1994;95-120. b.
16. Dilsaver S.C. Pathophysiology of "cholinoceptor supersensitivity" in affective disorders. Biol Psychiatry. 21:1986;813-829.
17. Dodt C., Hansen K., Uthgennant D., Born J., Fehm H.L. Cholinergic potentiation of the meal-related rise in ACTH and cortisol concentrations in men. Exp Clin Endocrinol. 102:1994;460-466.
18. Doerr P., Berger M. Physostigmine-induced escape from dexamethasone suppression in normal adults. Biol Psychiatry. 18:1983;261-268.
19. Fibiger H.C., Damsma G., Day J.C. Behavioral pharmacology and biochemistry of central cholinergic neurotransmission. Napier T.C., Kalivas P.W., Hanin I. The Basal Forebrain. 1991;399-414 Plenum Press, New York.
20. Freeman E., Touze R., Grossman A., Besser M., Ross R. Pyridostigmine, an acetyl-cholinesterase inhibitor, stimulates growth hormone release, but has no effect on basal thyrotrophin or adrenocorticotrophin levels, or the thyrotrophin response to thyrotrophin-releasing hormone. J Neuroendocrinol. 2:1990;429-432.
21. 8]-vasopressin in depressed patients and healthy subjects. Eur Neuropsychopharmacol. 2:1992;411-419.
22. Glick S.M., Kagan A. Radioimmunoassay of arginine vasopressin. Jaffe B.M., Behrmann H.R. Methods of Hormone Radioimmunoassays. 1979;341-351 Academic Press, New York.
23. Gregg C.M. The compartmentalized hypothalamo-neurohypophysial system. evidence for a neurohypophysial action of acetylcholine on vasopressin release Neuroendocrinology. 40:1985;423-429.
24. Gurwitz D., Egozi Y., Henis Y.I., Kloog Y., Sokolovsky M. Agonist and antagonist binding to rat brain muscarinic receptors. Influence of aging Neurobiol Aging. 8:1987;115-122.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6:1967;278-296.
26. Herman J.P., Prewitt C.M., Cullinan W.E. Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Crit Rev Neurobiol. 10:1996;371-394.
27. Heuser I.J., Gotthardt U., Schweiger U., Schmider J., Lammers C.H., Dettling M., Holsboer F. Age-associated changes of pituitary-adrenocortical hormone regulation in humans. Importance of gender Neurobiol Aging. 15:1994;227-231.
28. Hofman M.A. Lifespan changes in the human hypothalamus. Exp Gerontol. 32:1997;559-575.
29. Janowsky D.S., Overstreet D.H. The role of acetylcholine mechanisms in mood disorders. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;945-956 Raven Press, New York.
30. Kathol R.G., Jaeckle R.S., Lopez J.F., Meller W.H. Consistent reduction of ACTH responses to stimulus with CRH, vasopressin and hypoglycaemia in patients with major depression. Br J Psychiatry. 155:1989;468-478.
31. Koch K.L., Summy-Long J., Bingaman S., Sperry N., Stern R.M. Vasopressin and oxytocin responses to illusory self-motion and nausea in man. J Clin Endocrinol Metab. 71:1990;1269-1275.
32. Kohl R.L. Beta-endorphin and arginine vasopressin following stressful sensory stimuli in man. Aviat Space Environ Med. 63:1992;986-993.
33. Krieg J.-C., Bossert S., Pirke K.-M., von Zerssen D., Berger M. The influence of the muscarinic agonist RS 86 on the cortisol system. Biol Psychiatry. 22:1987;573-582.
34. Lewis D.A., Sherman B.M., Kathol R.G. Analysis of the specificity of physostigmine stimulation of adrenocorticotropin in man. J Clin Endocrinol Metab. 58:1984;570-573.
35. Michels K.M., Meeker R.B., Hayward J.N. Muscarinic cholinergic control of vasopressin secretion from the acute hypothalamoneurohypophysial explant. Neuroendocrinology. 54:1991;219-226.
36. Nurnberger J.I. Jr., Jimerson D.C., Simmons-Alling S., Tamminga C., Nadi N.S., Lawrence D., Sitaram N., Gillin J.C., Gershon E.S. Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and "well state" bipolar patients. Psychiatry Res. 9:1983;191-200.
37. Nussey S.S., Hawthorn J., Page S.R., Ang V.T., Jenkins J.S. Responses of plasma oxytocin and arginine vasopressin to nausea induced by apomorphine and ipecacuanha. Clin Endocrinol. 28:1988;297-304.
38. Ohmori N., Itoi K., Tozawa F., Sakai Y., Sakai K., Horiba N., Demura H., Suda T. Effect of acetylcholine on corticotropin-releasing factor gene expression in the hypothalamic paraventricular nucleus of conscious rats. Endocrinology. 136:1995;4858-4863.
39. Okuda H., Shioda S., Nakai Y., Nakayama H., Okamoto M., Nakashima T. The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals with nicotinic acetylcholine receptor-like immunoreactivity in the median eminence of the rat. Neurosci Lett. 161:1993;183-186.
40. Pascualy M., Peskind E.R., Wingerson D., van Belle G., Veith R.C., Dorsa D.M., Raskind M.A. Lack of cholinergic regulation of vasopressin and norepinephrine responses to hypertonic saline in humans. Psychoneuroendocrinology. 20:1995;679-691.
41. Peskind E.R., Raskind M.A., Wingerson D., Pascualy M., Thal L.J., Dobie D.J., Wilkinson C.W. Hypothalamic-pituitary-adrenocortical axis responses to physostigmine. Effects of Alzheimer's disease and gender Biol Psychiatry. 40:1996;61-68.
42. Poulain D.A., Lebrun C.J., Vincent J.D. Electrophysiological evidence for connections between septal neurones and the supraoptic nucleus of the hypothalamus of the rat. Exp Brain Res. 42:1981;260-268.
43. Raskind M.A., Peskind E.R., Veith R.C., Risse S.C., Lampe T.H., Borson S., Gumbrecht G., Dorsa D.M. Neuroendocrine responses to physostigmine in Alzheimer's disease. Arch Gen Psychiatry. 46:1989;535-540.
44. Raskind M.A., Peskind E.R., Veith R.C., Wilkinson C.W., Federighi D., Dorsa D.M. Differential effects of aging on neuroendocrine responses to physostigmine in normal men. J Clin Endocrinol Metab. 70:1990;1420-1425.
45. Risch S.C., Janowsky D.S., Gillin J.C. Muscarinic supersensitivity of anterior pituitary ACTH and β-endorphin release in major depressive illness. Peptides. 4:1983;789-792.
46. Rittmaster R.S., Cutler G.B., Gold P.W., Brandon D.D., Tomai T., Loriaux D.L., Chrousos G.P. The relationship of saline-induced changes in vasopressin secretion to basal and corticotropin-releasing hormone-stimulated adrenocorticotropin and cortisol secretion in man. J Clin Endocrinol Metab. 64:1987;371-376.
47. Rivier C., Smith M., Vale W. Regulation of adrenocorticotropic hormone (ACTH) secretion by corticotropin releasing factor (CRF). De Souza E.B., Nemeroff C.B. Corticotropin Releasing Factor. Basic and Clinical Studies of a Neuropeptide:1990;175-203 CRC Press, Boca Raton.
48. Rubin R.T., Poland R.E., Lesser I.M., Winston R.A., Blodgett A.L.N. Neuroendocrine aspects of primary endogenous depression I. Cortisol secretory dynamics in patients and matched control subjects Arch Gen Psychiatry. 44:1987;329-336.
49. Rubin R.T., Phillips J.J., Sadow T.F., McCracken J.T. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment Arch Gen Psychiatry. 52:1995;213-218.
50. Salata R.A., Jarrett D.B., Verbalis J.G., Robinson A.G. Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. J Clin Invest. 81:1988;766-774.
51. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview for DSM-III-R. 1990;American Psychiatric Press, Washington DC.
52. Sukhov R.R., Walker L.C., Rance N.E., Price D.L., Young W.S. III Vasopressin and oxytocin gene expression in the human hypothalamus. J Comp Neurol. 337:1993;295-306.
53. Swaab D.F. Development of the human hypothalamus. Neurochem Res. 20:1995;509-519.
54. Swaab D.F., Gooren L.J., Hofman M.A. Brain research, gender and sexual orientation. J Homosexuality. 28:1995;283-301.
55. Thompson L.M., Rubin R.T. Neuroendocrine aspects of primary endogenous depression XIII. Influence of race on differences in hypothalamo-pituitary-adrenal and pituitary-thyroid function between patients and matched controls Biol Psychiatry. 34:1993;893-895.
56. Thompson L.M., Rubin R.T., McCracken J.T. Neuroendocrine aspects of primary endogenous depression XII. Receiver operating characteristic and kappa analyses of serum and urine cortisol measures in patients and matched controls Psychoneuroendocrinology. 17:1992;507-515.
57. Tsagarakis S., Grossman A. Central neuroregulation of hypothalamic corticotropin-releasing hormone (CRH-41) secretion. J Endocrinol Invest. 13:1990;765-775.
58. Tuomisto J., Männistö P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev. 37:1985;249-332.
59. Viau V., Meaney M.J. The inhibitory effect of testosterone on hypothalamic-pituitary-adrenal responses to stress is mediated by the medial preoptic area. J Neurosci. 16:1996;1866-1876.
60. Wainer B.H., Steininger T.L., Roback J.D., Burke-Watson M.A., Mufson E.J., Kordower J. Ascending cholinergic pathways. Functional organization and implications for disease models Progr Brain Res. 98:1993;9-30.
61. Whitnall M.H. Regulation of the hypothalamic corticotropin-releasing hormone neurosecretory system. Progr Neurobiol. 40:1993;573-629.